Orient Europharma Co Ltd Cash Flow Conversion Efficiency
Orient Europharma Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Orient Europharma Co Ltd (4120) has a cash flow conversion efficiency ratio of -0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-157.84 Million ≈ $-4.97 Million USD) by net assets (NT$7.89 Billion ≈ $248.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Orient Europharma Co Ltd (2015–2024)
Cash flow conversion efficiency of Orient Europharma Co Ltd from 2015 to 2024. This chart illustrates how Orient Europharma Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Orient Europharma Co Ltd (4120) stock price for real-time trading data and today's change.
Orient Europharma Co Ltd Cash Flow Conversion Ratio Explained
Orient Europharma Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Orient Europharma Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orient Europharma Co Ltd ranked by their cash flow conversion efficiency. Also see how much is Orient Europharma Co Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MingZhu Logistics Holdings Ltd
NASDAQ:YGMZF
|
0.030x |
|
Alpine 4 Holdings Inc
NASDAQ:ALPP
|
-0.019x |
|
Mothercare PLC
LSE:MTC
|
0.109x |
|
Harvest Minerals Ltd
LSE:HMI
|
-0.192x |
|
Hornby PLC
LSE:HRN
|
0.163x |
|
Eos Energy Enterprises Inc
NASDAQ:EOSEW
|
0.028x |
|
Adomos SA
PA:ALADO
|
-0.008x |
|
Bolt Projects Holdings, Inc.
NASDAQ:BSLK
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Orient Europharma Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Orient Europharma Co Ltd from 2015 to 2024. Review cash generation quality of Orient Europharma Co Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.82 Billion ≈ $183.50 Million |
NT$-121.11 Million ≈ $-3.82 Million |
-0.021x | -233.83% |
| 2023-12-31 | NT$4.16 Billion ≈ $131.14 Million |
NT$64.67 Million ≈ $2.04 Million |
0.016x | +124.46% |
| 2022-12-31 | NT$3.44 Billion ≈ $108.50 Million |
NT$-218.75 Million ≈ $-6.89 Million |
-0.064x | -382.48% |
| 2021-12-31 | NT$3.45 Billion ≈ $108.79 Million |
NT$77.65 Million ≈ $2.45 Million |
0.022x | -85.57% |
| 2020-12-31 | NT$3.91 Billion ≈ $123.03 Million |
NT$608.55 Million ≈ $19.17 Million |
0.156x | +161.25% |
| 2019-12-31 | NT$3.81 Billion ≈ $120.09 Million |
NT$227.37 Million ≈ $7.16 Million |
0.060x | +6.82% |
| 2018-12-31 | NT$4.14 Billion ≈ $130.50 Million |
NT$231.31 Million ≈ $7.29 Million |
0.056x | -61.93% |
| 2017-12-31 | NT$4.10 Billion ≈ $129.11 Million |
NT$601.08 Million ≈ $18.94 Million |
0.147x | +416.37% |
| 2016-12-31 | NT$3.92 Billion ≈ $123.38 Million |
NT$111.24 Million ≈ $3.50 Million |
0.028x | -85.07% |
| 2015-12-31 | NT$3.38 Billion ≈ $106.63 Million |
NT$643.97 Million ≈ $20.29 Million |
0.190x | -- |
About Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplement… Read more